C
Chloe Orkin
Researcher at Queen Mary University of London
Publications - 229
Citations - 14129
Chloe Orkin is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 11614 citations. Previous affiliations of Chloe Orkin include Barts Health NHS Trust & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Samir K. Gupta,Frank A. Post,Jose R. Arribas,Joseph J. Eron,David A. Wohl,Amanda Clarke,Paul E. Sax,Hans-Jürgen Stellbrink,Stefan Esser,Anton Pozniak,Daniel Podzamczer,Laura Waters,Chloe Orkin,Jürgen K. Rockstroh,Tatiana Mudrikova,Eugenia Negredo,Richard Elion,Susan Guo,Lijie Zhong,Christoph C Carter,Hal Martin,Diana M. Brainard,Devi SenGupta,Moupali Das +23 more
TL;DR: This research presents a novel probabilistic procedure called “spot-spot analysis” that allows for real-time analysis of the response of the immune system to foreign substance abuse.
Journal ArticleDOI
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Chloe Orkin,Jean-Michel Molina,Eugenia Negredo,Jose R. Arribas,Joseph Gathe,Joseph J. Eron,Erika Van Landuyt,Erkki Lathouwers,Veerle Hufkens,Romana Petrovic,Simon Vanveggel,Magda Opsomer,Faiza Ajana,Jose R. Arribas,J. Bailey,P. Benson,Juan Berenguer,L. Bhatti,Anders Blaxhult,Indira Brar,U. F. Bredeek,Cynthia Brinson,Jason Brunetta,José L. Casado,Amanda Clarke,Brian Conway,Laurent Cotte,Gordon Crofoot,D. Cunningham,J. de Vente,S De Wit,Edwin DeJesus,Craig A. Dietz,Robin Dretler,J. J. Eron,Jan Fehr,Franco Antonio Felizarta,Carl J. Fichtenbaum,Leo Flamholc,Eric Florence,M. J. Galindo,Joel E. Gallant,J Gasiorowski,Gatell Jm,J. Gathe,Brian Gazzard,P-M Girard,Magnus Gisslén,Félix Gutiérrez,Mdm Gutierrez,Debbie Hagins,W. Halota,S. Henn,W.K. Henry,A Horban,G. Huhn,José Antonio Iribarren,Mamta K. Jain,Margaret A. Johnson,Christine Katlama,Marina B. Klein,Hernando Knobel,C. Lucasti,Claudia Martorell,Cheryl McDonald,Anthony Mills,J.-M. Molina,Javier O Morales-Ramirez,Karam Mounzer,M Moutschen,D. Murphy,Ronald Nahass,E Negredo,H. Olivet,C Orkin,Olayemi Osiyemi,Ignacio Pérez-Valero,A. Piekarska,Juan A. Pineda,Daniel Podzamczer,Isabelle Poizot-Martin,J. Portilla Sogorb,Frank A. Post,David James Prelutsky,Federico Pulido,Anita Rachlis,F Raffi,Moti Ramgopal,B. Rashbaum,Andri Rauch,D. Rey,Jacques Reynes,C. Ricart,Gary Richmond,Antonio Rivero,Peter Ruane,I. Santos Gil,Anthony John Scarsella,A. Scribner,Stephen D. Shafran,P. Shalit,David Shamblaw,Jihad Slim,Marcel Stoeckle,Karen T. Tashima,E. Teicher,A. Thalme,Andrew Ustianowski,E. Van Wijngaerden,Linos Vandekerckhove,Bernard Vandercam,G. Voskuhl,Sharon Walmsley,Doug Ward,L. Waters,Aimee M. Wilkin,A. Witor,Yazdan Yazdanpanah +117 more
TL;DR: The findings show the safety and efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide as a potential switch option for the treatment of HIV-1 infection in adults with viral suppression.
Journal ArticleDOI
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial
Nicholas I. Paton,Nicholas I. Paton,Wolfgang Stöhr,Alejandro Arenas-Pinto,Martin Fisher,Ian Williams,Margaret Johnson,Chloe Orkin,Fabian Chen,Vincent Lee,Alan Winston,Mark Gompels,Julie Fox,Karen Scott,David Dunn +14 more
TL;DR: Protease inhibitor monotherapy, with regular viral load monitoring and prompt reintroduction of combination treatment for rebound, preserved future treatment options and did not change overall clinical outcomes or frequency of toxic effects.
Journal ArticleDOI
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
Michael Aboud,Chloe Orkin,Daniel Podzamczer,Johannes R. Bogner,David Baker,Marie-Aude Khuong-Josses,David Parks,Konstantinos Angelis,Lesley P Kahl,Elizabeth A. Blair,Kimberly K. Adkison,Mark R. Underwood,Jessica E. Matthews,Brian Wynne,Kati Vandermeulen,Martin Gartland,Kimberly Y. Smith +16 more
TL;DR: The combination of dolutegravir plus rilpivirine sustained virological suppression of HIV-1, was associated with a low frequency ofVirological failure, and had a favourable safety profile, which support its use as a nucleoside reverse transcriptase inhibitor-sparing and protease inhibitor -sparing alternative to three-drug regimens that reduces overall exposure to ART.
Journal ArticleDOI
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
Andrew N. Phillips,Clifford Leen,A Wilson,Jane Anderson,David Dunn,Achim Schwenk,Chloe Orkin,Teresa Hill,Martin Fisher,John Walsh,Deenan Pillay,Loveleen Bansi,Brian Gazzard,Philippa Easterbrook,Richard Gilson,Margaret A. Johnson,Caroline A. Sabin +16 more
TL;DR: It is shown that extensive virological failure of the three main classes of drugs occurs slowly in routine clinical practice, having implications for the planning of treatment programmes in developing countries, where additional drugs outside these classes are unlikely to be available for some time.